Best Practice & Research Clinical Anaesthesiology
Volume 24, Issue 1 , Pages 41-50 , March 2010

Patients under anti-platelet therapy

  • Pierre Albaladejo, MD, PhD (Professor)

      Affiliations

    • Department of Anaesthesiology and Intensive Care, Grenoble University Hospital, Grenoble CEDEX 9, France
    • ,
  • Charles Marc Samama, MD, PhD, FCCP (Professor and Chairman)

      Affiliations

    • Department of Anaesthesiology and Intensive Care, Hotel-Dieu University Hospital, 1, place du Parvis de Notre-Dame 75181 Paris Cedex 04, France
    • Corresponding Author InformationCorresponding author. Tel.: +33 1 42 34 85 51, Mobile: +33 6 62 14 86 64; Fax: +33 1 42 34 89 60.

References 

  1. Nuttall GA, Brown MJ, Stombaugh JW, et al. Time and cardiac risk of surgery after bare-metal stent percutaneous coronary intervention. Anesthesiology. 2008;109:588–595
  2. Rabbitts JA, Nuttall GA, Brown MJ, et al. Cardiac risk of noncardiac surgery after percutaneous coronary intervention with drug-eluting stents. Anesthesiology. 2008;109:596–604
  3. Chassot PG, Delabays A, Spahn DR. Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction. British Journal of Anaesthesia. 2007;99:316–328
  4. Douketis JD, Berger PB, Dunn AS, et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:299S–339S
  5. Albaladejo P, Marret E, Piriou V, et al. Perioperative management of antiplatelet agents in patients with coronary stents: recommendations of a French Task Force. British journal of anaesthesia. 2006;97:580–582
  6. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. Circulation. 2007;116:1971–1996
  7. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126–2130
  8. Patrono C, Baigent C, Hirsh J, et al. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2008;133:199S–233S
  9. Patrono C, Coller B, FitzGerald GA, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:234S–264S
  10. Pena A, Collet JP, Hulot JS, et al. Can we override clopidogrel resistance?. Circulation. 2009;119:2854–2857
  11. Angiolillo DJ, Bhatt DL, Gurbel PA, et al. Advances in antiplatelet therapy: agents in clinical development. The American journal of cardiology. 2009;103:40A–51A
  12. Baigent C, Blackwell L, Collins R, et al. Antithrombotic Trialists' (ATT) Collaboration Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849–1860
  13. CAPRIE steering committee . A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348:1329–1339
  14. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. The New England Journal of Medicine. 2006;354:1706–1717
  15. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. The New England Journal of Medicine. 2007;357:2001–2015
  16. FitzGerald GA, Oates JA, Hawiger J, et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. The Journal of Clinical Investigation. 1983;71:676–688
  17. Cahill RA, McGreal GT, Crowe BH, et al. Duration of increased bleeding tendency after cessation of aspirin therapy. Journal of the American College of Surgeons. 2005;200:564–573
  18. Price MJ, Teirstein PS. Dynamics of platelet functional recovery following a clopidogrel loading dose in healthy volunteers. The American Journal of Cardiology. 2008;102:790–795
  19. Berger JS, Frye CB, Harshaw Q, et al. Impact of Clopidogrel in Patients With Acute Coronary Syndromes Requiring Coronary Artery Bypass. Journal of The American College of Cardiology. 2008;52:1693–1701
  20. Fatah K, Beving H, Albage A, et al. Acetylsalicylic acid may protect the patient by increasing fibrin gel porosity. Is withdrawing of treatment harmful to the patient?. European Heart Journal. 1996;17:1362–1366
  21. Beving H, Zhao C, Albage A, et al. Abnormally high platelet activity after discontinuation of acetylsalicylic acid treatment. Blood Coagulation & Fibrinolysis. 1996;7:80–84
  22. Vial JH, McLeod LJ, Roberts MS. Rebound elevation in urinary thromboxane B2 and 6-keto-PGF1 alpha excretion after aspirin withdrawal. Advances in Prostaglandin, Thromboxane, and Leukotriene Research. 1991;21A:157–160
  23. Louwerenburg JW, Suttorp MJ, Herie Kingma J. Aspirin withdrawal in a patient with essential thrombocythemia: possible cause of myocardial infarction. The American Journal of Medicine. 1987;83:1175
  24. Krnic-Barrie S, O'Connor CR, Looney SW, et al. A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis. Archives of Internal Medicine. 1997;157:2101–2108
  25. Collet JP, Montalescot G, Blanchet B, et al. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation. 2004;110:2361–2367
  26. Ferrari E, Benhamou M, Cerboni P, et al. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. Journal of the American College of Cardiology. 2005;45:456–459
  27. Bachman DS. Discontinuing chronic aspirin therapy: another risk factor for stroke?. Annals of Neurology. 2002;51:137–138
  28. Maulaz AB, Bezerra DC, Michel P, et al. Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. Archives of Neurology. 2005;62:1217–1220
  29. Sibon I, Orgogozo JM. Antiplatelet drug discontinuation is a risk factor for ischemic stroke. Neurology. 2004;62:1187–1189
  30. Albaladejo P, Geeraerts T, Francis F, et al. Aspirin withdrawal and acute lower limb ischemia. Anesthesia and Analgesia. 2004;99:440–443table of contents
  31. Kaluza GL, Joseph J, Lee JR, et al. Catastrophic outcomes of noncardiac surgery soon after coronary stenting. Journal of the American College of Cardiology. 2000;35:1288–1294
  32. Vicenzi MN, Meislitzer T, Heitzinger B, et al. Coronary artery stenting and non-cardiac surgery–a prospective outcome study. British Journal of Anaesthesia. 2006;96:686–693
  33. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369:667–678
  34. Ong AT, McFadden EP, Regar E, et al. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. Journal of the American College of Cardiology. 2005;45:2088–2092
  35. Eisenberg MJ, Richard PR, Libersan D, et al. Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents. Circulation. 2009;119:1634–1642
  36. Godet G, Le Manach Y, Lesache F, et al. Drug-eluting stent thrombosis in patients undergoing non-cardiac surgery: is it always a problem?. British Journal of Anaesthesia. 2008;100:472–477
  37. Schouten O, van Domburg RT, Bax JJ, et al. Noncardiac surgery after coronary stenting: early surgery and interruption of antiplatelet therapy. Journal of the American College of Cardiology. 2007;
  38. Pulmonary Embolism Prevention (PEP) Trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet. 2000;355:1295–1302
  39. Burger W, Chemnitius JM, Kneissl GD, et al. Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis. Journal of Internal Medicine. 2005;257:399–414
  40. Giannarini G, Mogorovich A, Valent F, et al. Continuing or discontinuing low-dose aspirin before transrectal prostate biopsy: results of a prospective randomized trial. Urology. 2007;70:501–505
  41. Ehrlich Y, Yossepowitch O, Margel D, et al. Early initiation of aspirin after prostate and transurethral bladder surgeries is not associated with increased incidence of postoperative bleeding: a prospective, randomized trial. The Journal of Urology. 2007;178:524–528discussion 528
  42. Samama CM, Bastien O, Forestier F, et al. Antiplatelet agents in the perioperative period: expert recommendations of the French Society of Anesthesiology and Intensive Care (SFAR). Canadian Journal of Anaesthesia. (Journal canadien d'anesthésie), 2001;2002(49):S26–S35
  43. O'Riordan JM, Margey RJ, Blake G, et al. Antiplatelet agents in the perioperative period. Archives of Surgery (Chicago, Ill:1960). 2009;144:69–76discussion 76
  44. Sobel M, Verhaeghe R, Physicians ACoC , et al. Antithrombotic therapy for peripheral artery occlusive disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2008;133:815S–843S
  45. Ebrahimi R, Dyke C, Mehran R, et al. Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. Journal of the American College of Cardiology. 2009;53:1965–1972
  46. Samama CM, Bonnin P, Bonneau M, et al. Comparative arterial antithrombotic activity of clopidogrel and acetyl salicylic acid in the pig. Thrombosis and Haemostasis. 1992;68:500–505
  47. Samama CM, Thiry D, Elalamy I, et al. Perioperative activation of hemostasis in vascular surgery patients. Anesthesiology. 2001;94:74–78
  48. Rosencher N, Vielpeau C, Emmerich J, et al. Venous thromboembolism and mortality after hip fracture surgery: the ESCORTE study. Journal of Thrombosis and Haemostasis. 2005;3:2006–2014

PII: S1521-6896(09)00072-X

doi: 10.1016/j.bpa.2009.09.008

Best Practice & Research Clinical Anaesthesiology
Volume 24, Issue 1 , Pages 41-50 , March 2010

Article Tools

* Image Usage & Resolution